A 78-year old male with ureteral carcinoma manifesting hypercalcemia is reported. He was diagnosed as having ureteral carcinoma of the left side 2 years previously and was treated by nephrectomy with ureterovesicostomy. In October 1991, he was admitted for anorexia. A clinical examination revealed recurrence of the ureteral carcinoma with metastasis to the rectum and liver. His serum calcium level was elevated (13.9 mg/dl). In addition to rehydration and furosemide, treatment with eel-calcitonin and prednisolone failed to decrease his serum calcium level. Finally, he was administered mithramycin but he died 13 days later. He had no evidence of bone metastasis or hyperparathyroidism. Nephrogenic CAMPand urinary parathyroid hormone-related protein (PTHrP) were markedly elevated. Immunohistochemical study demonstrated expression ofPTHrP in the tumor cells. Thus, the hypercalcemia was thought to be mediated by PTHrPsecreted from the neoplastic tumor. Although there have been several reports of ureteral carcinoma associated with humoral hypercalcemia of malignancy, this is considered to be the first case associated with elevation of PTHrP. (Internal Medicine 33: 107-109, 1994) 
Introduction
Hypercalcemiain association with neoplasmis not a rare phenomenon. More than 12.7% of renal cell carcinoma is reported to be associated with hypercalcemia ( 1 ) . Nevertheless, the occurrence of hypercalcemia with ureteral tumors has been poorly documented because of the relatively rare frequency of this neoplasm. Recently, the identification of parathyroid hormone-related protein (PTHrP) isolated from a lung cancer (2) or renal cancer cell line (3) enabled us to understand the etiology of humoral hypercalcemia of malignancy (HHM).The amino acid sequence of PTHrP shows sequence homology at its amino-terminus with that ofPTH (4, 5) and its potent PTH-like bioactivity is explained to be mediated via PTHreceptor. Here, we describe a patient with ureteral carcinoma associated with HHMdue to PTHrP.
Case Report
A 78-year-old male presented carcinoma of the left ureter in March 1990. His serum calcium level and liver function tests were normal at this time. He underwent left nephrectomy and ureterovesicostomy. Pathological examination revealed a transitional cell carcinoma of the left ureter (Fig. 1) . He was not given further chemotherapy and radiotherapy because of his advanced age. He remained well for a year and a half. In October 1991, he complained of anorexia and lassitude and was admitted to our hospital. Physical examination revealed an enlarged irregular liver, mild retention of ascites and dry skin. His laboratory studies on admission indicated anemia, mild leukocytosis and markedly elevated levels of transaminases, LDH, and AL-P (Table 1) . Furthermore, he was hypercalcemic (12.9 mg/dl, corrected calcium level: 13.9 mg/dl) with a normal serum phosphorus level (3.9 mg/dl). His serum creatinine was marginally raised to 2.5 mg/dl. His urinalysis represented no abnor- immunoperoxidase method was performed using anti-PTHrP antibody. A few carcinoma cells in the rectal polyp revealed immunohistochemical expression of PTHrP (Fig. 3) . Thus, he was considered to be in the state of HHM due to PTHrP producing tumor.
His hypercalcemia was first treated with rehydration with saline. In addition, furosemide, prednisolone and eel-calcitonin were administrated, however his serum calcium level continued to rise. Finally, his serum calcium level reached 20.1 mg/ dl, and he fell into unconsciousness. Despite administration of PTHrP Producing Ureteral Tumor mithramycin, his hypercalcemia was uncontrollable. He developed arrhythmia and cardiac arrest and died 13 days later. An autopsy was not performed.
Discussion
Hypercalcemiais a common complication in patients with cancer and metastatic deposit in bone, that is termed local osteolytic hypercalcemia. However, in most patients with cancer manifesting hypercalcemia, no detectable bone metastasis is found, and its cause is considered to be humoral. In such cases, removal of the tumor results in remission of the hypercalcemia and the later reappearance of tumor recurrence. The etiology of humoral hypercalcemia is postulated to be caused by mediators that increase bone resorption such as PTHrP, 1 ,25 dihydroxy vitamin D3 (6), interleukin 1 (7), tumor necrosis factor (8), transforming growth factor (9), prostaglandin E ( 1 0) and prostaglandin-stimulating factors ( 1 1 ). Amongthese factors, only PTHrP possesses PTH-like bioactivity. In this case, no bone metastasis was found, and nephrogenic CAMP was markedly elevated despite the suppressed level of PTH. Furthermore, PTHrPin his urine was markedly elevated and immunohistochemical study demonstrated expres sion ofPTHrP in the tumor cells. Thus, it is most likely that in this case, PTHrP secreted from neoplastic tissue interacted with the PTH receptors to give rise to hypercalcemia. However, the involvement of the other factors can not be excluded, since the white blood cell count was increased without evidence of infection. Bennett et al.reported two cases of bladder cancer associated with HHMand leukemoid reaction without evidence of bone metastasis, although the humoral factors were not determined (12) . At the onset, his serum calcium level was not elevated, and it did not change after resection of the tumor. Although the neoplastic tissue might have secreted PTHrPat that time, an increase in the urinary calcium excretion would prevent elevation of his serum calcium level. It is less likely that the character of the neoplasmchangedafter operation because no significant change in pathological findings was observed in the specimens obtained at the operation and the recurrence. Hypercalcemia associated with urogenital tumor is not rare (13) . Prostatic carcinoma is often associated with bone metastasis and hypercalcemia caused by local osteolytic lesions. Renal cell carcinoma is considered to be often associated with HHM. However, the pathogenesis of the hypercalcemia has been unknown until the discovery of PTHrP. Transitional cell carcinomaof the ureter is an uncommon tumoramongurogenital tumors. To our knowledge, this case is the first case ofureteral carcinoma associated with humoral hypercalcemia of malignancy (HHM) by PTHrP. Although removal or destruction of the neoplastic tissue is the primary treatment, rehydration with saline in combination of furosemide is thought to be effective as the initial treatment. Avariety of treatments were used in this case, such as eelcalcitonin, prednisolone and mithramycin. Regretfully, those therapies failed to overcomethe increase in the serum calcium level. Bone resorption is increased in patients with HHM, so that inhibition of osteoclast by bisphosphonate is considered to be an appropriate and effective treatment modality ( 14-1 6). We could not use this drug for this patient because the usage of this drug was limited in Japan at that time. An intravenous bisphosphonate therapy will supersede the traditional and often unsatisfactory therapeutic regimens ofrehydration, furosemide and prednisolone.
